Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

Overview of attention for article published in Lancet Oncology, November 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
Good Attention Score compared to outputs of the same age and source (78th percentile)

So far, Altmetric has seen 3 public wall posts from 3 users.

【卵巣がん】未治療の人で、標準的な化学療法にTKI阻害薬「オフェブ」の追加併用を選択することで、無増悪生存期間の延長が期待できる。試験では16.6ヵ月から17.2ヵ月に延長。〔Lancet Oncol〕 https://t.co/bCbNQ8KEZD

http://www.sciencedirect.com/science/article/pii/S1470204515003666 AGOがIIB期〜IV期の卵巣癌患者を対象に実施した TC vs TC＋Nintedanibの第III相比較試験の結果がp…

Standard first-line chemotherapy with or without nintedanib for advanced ovarian https://t.co/llwQ2yQ8GK #hvhebron #onco @TheLan…

This page shows the most recent Facebook posts that mention this research output. Click here to find out how to access more activity.